DISCOVERY

Request webinar recordings

Webinars and abstracts

Streamline molecular discovery: An introduction to Cresset Discovery

Complementing internal research by oursourcing all or part of your computational chemistry can accelerate the commercialization of research assets. Learn how Cresset Discovery CADD scientists work with discovery teams in the pharmaceutical, agrochemical and flavor and fragrances industries to deliver their corporate objectives, by navigating bottlenecks and bringing fresh ideas to a project.

Streamline collaboration and information delivery of outsourced discovery projects

Collaboration, security of data and communication are all critical when outsourcing a molecular discovery project, particularly where biological data, chemical structures and use of multiple tools are concerned. Learn how Cresset Discovery ensures efficient collaboration and information delivery between multiple teams and sites by applying the Torx™ chemistry aware platform for small molecule discovery to your project.

Why do FEP yourself? The business case for outsourcing FEP calculations

The power of Free Energy Perturbation (FEP) to facilitate ligand design has been widely demonstrated, but effective implementation of this method requires computational chemistry expertise. Cresset Discovery CADD scientists work with your in-house research team, to offer expertise in the application of FEP methods and save you valuable time on lead generation or fragment optimization. Instead, your team can focus their efforts on designing compounds and advancing your drug discovery projects efficiently and cost effectively.

Discovering a novel therapy for urinary tract infections through outsourcing in-silico drug discovery

Serious bacterial infections represent a worldwide threat, due mainly to the emergence of antibiotic-resistant bacteria for which there are limited therapies. Urinary Tract Infections (UTIs) are among the most prevalent bacterial infections, affecting 150 million people per year, with 75% of infections occurring due to uropathogenic E. coli. 

Learn how a collaboration between the University of Cambridge and Cresset Discovery, combining cutting edge research with in-silico drug discovery expertise, successfully identified a set of novel inhibitors and, in a proof of concept, confirmed their ability to reduce pathogenicity in clinical strains of uropathogenic E. coli.

Request recordings

Contact us for a free confidential discussion

We help you reach your next milestone faster and more cost effectively

Contact us for a free confidential discussion
Discovery Services